

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4, Ankleshwar – 393 002, Gujarat, India

Tel: +91-7045456789 / 7046456789

Web: www.samratpharmachem.com CIN: L24230GJ1992PLC017820

Corporate Office

701/702, Business Square, M. A. Road, Andheri (West), Mumbai – 400 058, India

Tel: (91-22) 26701050 / 1 / 2 / 3 Email: contact@samratpharmachem.in

March 16, 2023

To,
Department of Corporate Services,
BSE Limited
P J Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Code: 530125

Dear Sir,

Sub: Outcome of Board Meeting held today

We wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Thursday, March 16, 2023, has appointed the following Directors on the recommendation of the Nomination and Remuneration Committee, details of which are as under:

1. Mr. Lalit Mehta (DIN: 00216681) re-appointed as the Chairman & Managing Director of the Company for a period of 3 years commencing from 1st April, 2023, on the terms and conditions including remuneration as approved by the Nomination and Remuneration Committee of the Board. This appointment is subject to the approval of the members of the Company.

Details of the appointee pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Name: Mr. Lalit Mehta (DIN: 00216681)					
а	Reason for change	Appointed as Chairman and Managing Director of			
		the Company with effect from 1st April, 2023.			
b	Date of appointment & term of	For a period of 3 years from 1st April, 2023 till 31st			
	appointment	March, 2026			
С	Brief Profile (in case of appointment)	Mr. Lalit Mehta aged 87 years is a Science & Law Graduate. He is a first generation entrepreneur. He is also a Promoter of the Company. He has over 55 years of experience in the pharmaceutical industry. He has brought a keen vision & direction to the company.			



Manufacturers & Exporters of Pharmaceutical Chemicals

		He is the Chairman & Managing Director of the Company since incorporation of the company. His rich experience in the pharmaceutical and chemical industry will be of immense benefit to the Company.
		Mr. Lalit Mehta is not debarred from holding the office of Director by virtue of any SEBI order or order by any other competent authority.
d	Disclosure of relationships between directors	Not related to any Director or Key Managerial Personnel of the Company except Mr. Rajesh Mehta and Mr. Megh Mehta, Executive Directors Father of Mr. Rajesh Mehta Grandfather of Mr. Megh Mehta

2. Mr. Rajesh Mehta (DIN: 00216731) re-appointed as the Executive Director of the Company for a period of 3 years commencing from 1st April, 2023, on the terms and conditions including remuneration as approved by the Nomination and Remuneration Committee of the Board. This appointment is subject to the approval of the members of the Company.

Details of the appointee pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Name: Mr. Rajesh Mehta (DIN: 00216731)				
а	Reason for change	Appointed as Executive Director of the Company with effect from 1st April, 2023.		
b	Date of appointment & term of appointment	For a period of 3 years from 1 st April, 2023 till 31 st March, 2026		
С	Brief Profile (in case of appointment)	Mr. Rajesh Mehta aged 58 years is a Commerce Graduate and a qualified Chartered Accountant. He has over 30 years of experience in Finance, Corporate Affairs & MIS. He is the Executive Director of the Company since incorporation of the company. His rich experience in the pharmaceutical and chemical industry will be of immense benefit to the Company.		
		Mr. Rajesh Mehta is not debarred from holding the office of Director by virtue of any SEBI order or order by any other competent authority.		
d	Disclosure of relationships between directors	Not related to any Director or Key Managerial Personnel of the Company except Mr. Lalit Mehta, Chairman & Managing Director and Mr. Megh Mehta, Executive Director Son of Mr. Lalit Mehta Father of Mr. Megh Mehta		



Manufacturers & Exporters of Pharmaceutical Chemicals

3. Mr. Megh Mehta (DIN: 07287394) re-appointed as the Executive Director of the Company for a period of 3 years commencing from 1st April, 2023, on the terms and conditions including remuneration as approved by the Nomination and Remuneration Committee of the Board. This appointment is subject to the approval of the members of the Company.

Details of the appointee pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Name	Name: Mr. Megh Mehta (DIN: 07287394)					
а	Reason for change	Appointed as Executive Director of the Company with effect from 1st April, 2023.				
b	Date of appointment & term of appointment					
С	Brief Profile (in case of appointment)	Mr. Megh Mehta aged 30 years has a Bachelor's Degree in Management Studies (BMS), Master's Degree in Commerce (MCom) & Post Graduation in Professional Management (PGPM). He has over 8 years of experience in Marketing & Administration. He is the Executive Director of the Company since 2015. His experience in marketing of pharmaceutical products will be of immense benefit to the Company.				
		Mr. Megh Mehta is not debarred from holding the office of Director by virtue of any SEBI order or order by any other competent authority.				
d	Disclosure of relationships between directors	Not related to any Director or Key Managerial Personnel of the Company except Mr. Lalit Mehta, Chairman & Managing Director and Mr. Rajesh Mehta, Executive Director Grandson of Mr. Lalit Mehta Son of Mr. Rajesh Mehta				

Consequent to the above, the revised composition of the Board of Directors of the Company with effect from 1st April, 2023 will be:

Mr. Lalit Mehta	Chairman & Managing Director	DIN: 00216681
Mr. Rajesh Mehta	Executive Director	DIN: 00216731
Mr. Megh Mehta	Executive Director	DIN: 07287394
Mr. Mahendra Pipalia	Independent Director	DIN: 00216959
Mr. Samir Kothary	Independent Director	DIN: 00216603
Ms. Renu Dharod	Independent Director	DIN: 07063088

The above appointment of the Executive Directors will be subject to approval of members through the forthcoming Postal Ballot Meeting.



Manufacturers & Exporters of Pharmaceutical Chemicals

The Board has adopted Succession Planning Policy under Regulation 17(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "LODR Regulations") effective from 16th March, 2023.

The meeting of the Board of Directors of the Company commenced at 14:00 hrs and concluded at 15:30 hrs.

Kindly inform all your members.

Thanking you,

Yours faithfully, For Samrat Pharmachem Limited

Nishant Kankaria Company Secretary & Compliance Officer